Skip to main navigation

>> Site Menu

  • Our Company
  • Our Science
  • Our Products
  • Join Us
  • INVESTORS & MEDIA
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • Investor Resources
Kodiak Sciences

>> Site Menu

  • Our Company
  • Our Science
  • Our Products
  • Join Us
  • INVESTORS & MEDIA
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • Investor Resources

News Releases

> News - Sub Nav

  • Press Releases

News Releases

October 3, 2018
Kodiak Sciences Inc. Announces Pricing of Initial Public Offering
Additional Formats
PDF Version
September 17, 2018
Kodiak Sciences Expands Leadership with Industry Veterans Including Appointment of Jason Ehrlich, M.D., Ph.D., as Chief Medical Officer and Chief Development Officer
Additional Formats
PDF Version
September 7, 2018
Kodiak Sciences Files Registration Statement for Proposed Initial Public Offering
Additional Formats
PDF Version
July 18, 2018
Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors
Additional Formats
PDF Version
April 27, 2018
Kodiak Sciences Inc. Announces Presentations at ARVO 2018 Annual Meeting
Additional Formats
PDF Version
April 26, 2018
Kodiak Sciences Completes $33 Million Mezzanine Private Financing
Additional Formats
PDF Version
February 8, 2016
Kodiak Sciences Inc. and Lonza Announce Agreements for the Development and Manufacture of Medicines for the Treatment of Retinal Disease
Additional Formats
PDF Version
January 12, 2016
Kodiak Sciences Inc. Closes Series B Financing to Fuel Retina Pipeline
Additional Formats
PDF Version
September 8, 2015
Oligasis LLC Becomes Kodiak Sciences Inc.
Additional Formats
PDF Version

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
Displaying 61 - 69 of 69
 
 
 
Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter
Copyright © 2021 Kodiak Sciences Inc.